{"ticker": {"uuid": "d81b17e9-f86d-4599-8d13-7059b2c8dfbd", "symbol": "MBRX", "name": "Moleculin Biotech Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOWXk4aklwck0tTWtFYkluLThYNGtxX3RHTHE0YlM2WnFRZG1YTk5mSW5oLVgzVGI3VW4zcTJVeWRDX2JyYWxLaVZ3cEVZS1k3OW56dkZqTnAtS2d4bzY1c2hOdTQ4c0FmeDF5Njdlam1KZURTSGNJMzZPQU9FY18tX3QxUzdCbmVfbEpMbWdJamZIVUVTVkVOUWhvTTN2LUs3Zmx0VG41dWo3Zw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-23T11:18:04+00:00", "published_display": "23 Jul 2026 11:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of Moleculin Biotech, Inc. \u2013 GETTEX:MOL0", "summary": "This article provides the \"Price to sales forward\" metric for Moleculin Biotech, Inc. (MOL0) on the GETTEX exchange. The content is primarily a data point embedded within a larger financial platform, indicating a value of \"No trades\" for the specified period.", "url": "https://www.tradingview.com/symbols/GETTEX-MOL0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T07:12:16", "published_display": "13 Jul 2026 07:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Moleculin Biotech, Inc. \u2013 GETTEX:MOL0", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Moleculin Biotech, Inc. (GETTEX:MOL0). The main content consists of the company name, stock ticker, and the specific financial metric. The article is from TradingView and indicates a market-closed status f", "url": "https://www.tradingview.com/symbols/GETTEX-MOL0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T22:09:31", "published_display": "12 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Moleculin Biotech, Inc. \u2013 GETTEX:MOL0", "summary": "This article displays the \"Price to book forward\" for Moleculin Biotech, Inc. (GETTEX:MOL0). It presents a data point under the \"Financials\" section for a specific period, detailing its value and change percentages. The content is presented within the TradingView platform, focusi", "url": "https://www.tradingview.com/symbols/GETTEX-MOL0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T19:39:55", "published_display": "11 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did MBRX Stock Climb 14% Today?", "summary": "Moleculin Biotech's stock (MBRX) surged 14% after the company announced it is on track to treat the 45th patient in its Miracle study for Annamycin by Q1 2026. The drug is being investigated for acute myeloid leukemia, with preliminary data showing a 40% complete remission rate i", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-mbrx-stock-climb-today/cZR0CkIR4vA", "source_name": "Stocktwits", "published_at": "2026-07-11T18:40:04", "published_display": "11 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Moleculin Biotech, Inc. \u2013 NASDAQ:MBRX", "summary": "This article provides financial data for Moleculin Biotech, Inc. (NASDAQ: MBRX), specifically focusing on its enterprise value to EBITDA forward. The content is presented within the TradingView platform, detailing financial metrics, market information, and company background for ", "url": "https://www.tradingview.com/symbols/NASDAQ-MBRX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T06:45:58", "published_display": "09 Jul 2026 06:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Moleculin Biotech, Inc. \u2013 LSE:0K2H", "summary": "This article displays the \"Price to earnings forward\" metric for Moleculin Biotech, Inc. (LSE:0K2H) on the TradingView platform. The content primarily shows navigation elements and structural information from the platform, indicating where this financial data would be presented. ", "url": "https://www.tradingview.com/symbols/LSE-0K2H/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T00:41:07", "published_display": "08 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech focuses on oncology pipeline and Nasdaq listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQSFh6VWU2Yk5lTVpzem15bWI5clBBRkVoTkNYbFZLekkzdFFZeXBEVUV2XzlXbHFZNTNraGV5NGtnRDlDZTllOEZDVmxFZFp1cWpfOWRiS3ctLUZyOWJGd2hBNjBwYkRIMUVPWmpBQ3Zfa0JBaExUMEhaZkNWV01rZTNXelBqOUJULTcyZHY5emhxa0cteTNNc05Pb3NyeFczNkMxc0RveEI3WV9CY1FUc1FpMUhTOUE3X3BrTENGM29Cdw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin CEO, Walter Klemp, Highlights Positive", "summary": "Moleculin's CEO, Walter Klemp, discussed positive preliminary results from the MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML) during a Virtual Investor \"What This Means\" segment. He highlighted early efficacy trends, summarized key data, an", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322423/0/en/moleculin-ceo-walter-klemp-highlights-positive-preliminary-miracle-trial-results-in-virtual-investor-what-this-means-segment.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T05:45:58", "published_display": "07 Jul 2026 05:45", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor \"What This Means\" Segment", "summary": "Moleculin Biotech, Inc. CEO, Walter Klemp, discussed positive preliminary efficacy results from the MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML) during a Virtual Investor \"What This Means\" segment. He highlighted the significance of early", "url": "https://www.sahmcapital.com/news/content/moleculin-ceo-walter-klemp-highlights-positive-preliminary-miracle-trial-results-in-virtual-investor-what-this-means-segment-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-06T15:33:00", "published_display": "06 Jul 2026 15:33", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor 'What This Means' Segment", "summary": "Moleculin Biotech, Inc. CEO, Walter Klemp, discussed positive preliminary unblinded efficacy results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML). He provided insights into ear", "url": "https://www.manilatimes.net/2026/07/06/tmt-newswire/globenewswire/moleculin-ceo-walter-klemp-highlights-positive-preliminary-miracle-trial-results-in-virtual-investor-what-this-means-segment/2379051/amp", "source_name": "The Manila Times", "published_at": "2026-07-06T13:09:54", "published_display": "06 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segment", "summary": "Moleculin Biotech's CEO, Walter Klemp, discussed positive preliminary unblinded efficacy results from the first 45 patients in the pivotal Phase 2/3 MIRACLE trial for Annamycin, a treatment for relapsed or refractory acute myeloid leukemia (R/R AML). While the preliminary data sh", "url": "https://www.quiverquant.com/news/Moleculin+Biotech+CEO+Discusses+Preliminary+MIRACLE+Trial+Results+for+Annamycin+in+Virtual+Investor+Segment", "source_name": "Quiver Quantitative", "published_at": "2026-07-06T12:44:00", "published_display": "06 Jul 2026 12:44", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin says early MIRACLE trial data support Annamycin in leukemia", "summary": "Moleculin CEO Walter Klemp discussed positive preliminary efficacy results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML). The discussion highlighted early efficacy trends across", "url": "https://www.stocktitan.net/news/MBRX/moleculin-ceo-walter-klemp-highlights-positive-preliminary-miracle-jfdzs9iv2o74.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:41:42", "published_display": "06 Jul 2026 12:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech | 8-K: Current report", "summary": "This document is an 8-K filing by Moleculin Biotech, indicating a current report with the SEC. It likely contains information on significant events or changes within the company that shareholders should be aware of.", "url": "https://www.moomoo.com/news/notice/307476918/moleculin-biotech-8-k-current-report", "source_name": "Moomoo", "published_at": "2026-07-06T05:09:54", "published_display": "06 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MBRX - Moleculin Biotech Inc Dividends", "summary": "This article provides comprehensive financial data for Moleculin Biotech Inc (MBRX), including its last close price, market capitalization, income, sales, key financial ratios, and performance metrics. It details the company's dividend estimates, earnings per share, insider and i", "url": "https://finviz.com/stock?t=MBRX&ty=dv&p=w", "source_name": "Finviz", "published_at": "2026-07-04T13:10:14", "published_display": "04 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annamycin boosts remission in Moleculin (MBRX) pivotal AML MIRACLE trial interim", "summary": "Moleculin Biotech (MBRX) reported positive interim results from its pivotal Phase 2/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (AML), showing Annamycin achieved significantly higher remission rates compared to the control arm after a single treatment cycle.", "url": "https://www.stocktitan.net/sec-filings/MBRX/8-k-moleculin-biotech-inc-reports-material-event-2d3624e9981d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:45", "published_display": "02 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10", "summary": "Maxim Group has reiterated its Buy rating for Moleculin Biotech (MBRX.US) and maintained its target price at $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72348333/maxim-group-maintains-moleculin-biotech-mbrxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-02T02:22:18", "published_display": "02 Jul 2026 02:22", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin reports positive interim data from AML trial", "summary": "Moleculin Biotech, Inc. announced positive interim data from the first 45 patients in Part A of its Phase 2/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia, causing its stock to surge. The trial's experimental Annamycin arms showed higher complete remission rate", "url": "https://www.investing.com/news/company-news/moleculin-reports-positive-interim-data-from-aml-trial-93CH-4767922", "source_name": "Investing.com", "published_at": "2026-07-01T03:39:11", "published_display": "01 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. Financial Disclosures & Filings", "summary": "This page provides an extensive list of Moleculin Biotech, Inc.'s financial disclosures and regulatory filings, including earnings reports, corporate presentations, and study updates from 2022 to 2026. The documents offer insights into the company's performance, strategy, and adv", "url": "https://www.tradingview.com/symbols/LSE-0K2H/documents/", "source_name": "TradingView", "published_at": "2026-07-01T02:32:40", "published_display": "01 Jul 2026 02:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance", "summary": "Shares of Moleculin Biotech (MBRX) plunged over 25% after interim data from its Annamycin clinical trial for acute myeloid leukemia did not achieve statistical significance, despite showing a trend favoring the drug. The company emphasized that more data from additional patients ", "url": "https://stocktwits.com/news-articles/markets/equity/mbrx-stock-drops-as-moleculin-biotech-interim-cancer-trial-data-falls-short-of-significance/cZ1QYEmR70m", "source_name": "Stocktwits", "published_at": "2026-06-30T18:52:00", "published_display": "30 Jun 2026 18:52", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 \"Miracle\" clinical trial, showing positive data.", "summary": "Moleculin Biotech, Inc. (Moleculin) has announced positive interim analysis results from its phase 2/3 \"Miracle\" clinical trial. The core candidate drug, Annamycin, demonstrated significantly superior efficacy in inducing complete remission for acute myeloid leukemia, achieving a", "url": "https://www.bitget.com/amp/news/detail/12560605483769", "source_name": "Bitget", "published_at": "2026-06-30T14:40:56", "published_display": "30 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. Shares June 2026 Investor Presentation and Key Regulatory Updates", "summary": "Moleculin Biotech, Inc. has released an investor presentation and provided key regulatory updates. The company received approximately $2.7 million from warrant exercises, increasing its outstanding shares to 7,065,000. These updates are intended to inform investors about the comp", "url": "https://www.minichart.com.sg/2026/06/30/moleculin-biotech-inc-shares-june-2026-investor-presentation-and-key-regulatory-updates/", "source_name": "Minichart", "published_at": "2026-06-30T13:02:00", "published_display": "30 Jun 2026 13:02", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Reports Positive Phase 2/3 MIRACLE Interim", "summary": "Moleculin Biotech, Inc. announced positive preliminary unblinded efficacy results from the", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319693/0/en/moleculin-reports-positive-phase-2-3-miracle-interim-results-with-annamycin-complete-remission-rates-3-fold-greater-than-control.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:39:40", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8-K Moleculin Biotech, Inc. For: Jun 30", "summary": "Moleculin Biotech, Inc. filed a Form 8-K announcing positive preliminary unblinded efficacy results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin. The study, analyzing 45 patients with relapsed or refractory acute myeloid leukemia (R/R AML), showed favorable ef", "url": "https://www.streetinsider.com/SEC+Filings/Form+8-K+Moleculin+Biotech%2C+Inc.+For%3A+Jun+30/26710215.html", "source_name": "StreetInsider", "published_at": "2026-06-30T12:39:40", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech (NASDAQ: MBRX) raises $2.7M as 1.36M warrants are exercised", "summary": "Moleculin Biotech (NASDAQ: MBRX) has reported raising approximately $2.7 million from the exercise of warrants covering 1.36 million shares of common stock. Following these exercises, the company now has 7,065,000 shares of common stock outstanding as of June 29, 2026. Moleculin ", "url": "https://www.stocktitan.net/sec-filings/MBRX/8-k-moleculin-biotech-inc-reports-material-event-639e24daf682.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:11:03", "published_display": "30 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX)", "summary": "This article provides an overview of Moleculin Biotech, Inc. (NASDAQ: MBRX) stock, including its current price, historical performance, analyst forecasts, and financial data. It details recent earnings, revenue, net income, and market capitalization, while also answering frequent", "url": "https://www.tradingview.com/symbols/NASDAQ-MBRX/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-29T09:11:56", "published_display": "29 Jun 2026 09:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control", "summary": "Moleculin Biotech, Inc. announced positive preliminary unblinded efficacy results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (R/R AML). Both Annamycin treatment arms demonstrated significantly high", "url": "https://finance.yahoo.com/healthcare/articles/moleculin-reports-positive-phase-2-123000165.html", "source_name": "Market source", "published_at": "2026-06-28T09:09:38", "published_display": "28 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MBRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a stock forecast for Moleculin Biotech, Inc. (MBRX), including analyst price targets, historical performance, and key financial data. It notes that analysts predict a maximum price of $22.00 and a minimum of $10.00 for MBRX. The company's current stock price", "url": "https://www.tradingview.com/symbols/NASDAQ-MBRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T03:40:37", "published_display": "27 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "0K2H Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Moleculin Biotech, Inc. (0K2H) stock, listed on the London Stock Exchange. It includes analyst ratings, future price estimates, and key financial metrics such as earnings, revenue, and market capitalization. The stock's perfor", "url": "https://www.tradingview.com/symbols/LSE-0K2H/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T00:39:26", "published_display": "26 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. Actuals & Estimates (LSE:0K2H)", "summary": "This article provides an overview of Moleculin Biotech, Inc. (LSE:0K2H) stock performance, financial actuals, and analyst estimates. It details recent price changes, historical highs and lows, market capitalization, and upcoming earnings reports. The piece also includes frequentl", "url": "https://www.tradingview.com/symbols/LSE-0K2H/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:47", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech (MBRX) CFO exercises RSUs, uses shares to cover taxes", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQLW9lN05HZ09mWUNid3dtVW14Zl90LWp3WDk4cFkzR29YMlRBb096TXA2dzZqTkZrelhUeUUzc0I0NTE4SUtnakctSkVidkJtVkhyS201N1lIZ2ppZndOLWhiaGJlYWxpc3Z0ZzVibndqelI4ZHVvN1NHOUlmQjNtNEt2aEUtLTc2Mko3ODZjLU5lNUtHWjZHX0dUdUZUSG1xZ2hqbUlpSko5UXMyeElwMHNCa2ZrUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech (MBRX) CEO reports RSU vesting, tax-share withholding and retained stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPcWhFalNhNDVLeUtJYmQ4QXgzX1VIVTNlbmtYbVJCWnQ4SGFNcTVIQnNnWm40MWhfNU5uYUNRSG9wdUtxcXk1dDJmVVVNUTVDU2ZRSVhtY20tS29YUTRWUHNueFByNmMyOG1DUC0xbVp4VDVZSTdKOWljVnVHVE1lSFNZMEJ2cC1xcUwzbzdpOWx5S1U1S003ZGNMeGRQUnVKUVpKQlEtbTQtbTA0Z1FraGcyRFc2UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | Moleculin Biotech Shoots up 106.41% Pre-Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOWjRJWHNERUx2RkYzOWZQZ0RxZ25ZbU5pOTA0N1ZnTXFfellQcERQLWFoNmR0dDY1cUhVRTNCU21KRUNKZXpnblhCUzdsWHltdzFlRlhiYjhyNWQ5R3R5aWNjWnJnS2JXNHNWS1NXNlFXVm1WMUpHYTNwV3J6Ymc1SW53MlRsLU1HWWRMMENxT2hEN1dSUFZCZndUY3dBajVrUHpNdQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Moleculin Biotech (MBRX.US)$", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNVGFtVDRad014Y2NJUzR6M2cyRHduOWVJWW9KX0pUVzJ5cUl4ZFBZTTBRaFNjclRIcFdlaW5fWWFnNFJyX0dUUjFtODVSZVJ6X19tVnRkVF92RjQzS2I1MDN2OVp6NE1uTDAtaFBwZVhCV0ZNRFFRTGo5LVBFX1lSNWJ0aHdOQQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/independent-market-research-finds-strong-122900069.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T12:29:00+00:00", "published_display": "05 Jun 2026 12:29", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/moleculin-ceo-walter-klemp-highlights-123100538.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:31:00+00:00", "published_display": "04 Jun 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/moleculin-presents-asco-2026-data-122100249.html", "source_name": "GlobeNewswire", "published_at": "2026-05-29T12:21:00+00:00", "published_display": "29 May 2026 12:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/moleculin-highlights-abstract-accepted-poster-210200148.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:02:00+00:00", "published_display": "21 May 2026 21:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/moleculin-reports-first-quarter-2026-123000136.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T12:30:00+00:00", "published_display": "15 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding", "summary": "", "url": "https://finance.yahoo.com/news/nano-cap-moleculin-biotech-approaches-164146755.html", "source_name": "Benzinga", "published_at": "2026-05-13T16:41:46+00:00", "published_display": "13 May 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks", "summary": "", "url": "https://finance.yahoo.com/news/moleculin-announces-imminent-miracle-trial-120000284.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T12:00:00+00:00", "published_display": "13 May 2026 12:00", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech (MBRX) Approaches Key Data Release in AML Tria", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQX2pFbHNKMzRQbkhBNm1LMmJBbC0xaEhQeEl4Tkh6UlhBb3RvNk5KRHgyWFRjcEtBOWl1ZHNndlVPNTc2OG9EbEFhRzVfSk9fY1BENmRhbFV6amUzSDNXdzVwelJISWNnaU5hamctUlM2TzNBa2h4Nk5XajVXVWdlVUFXWk5DWEYtYUNheVYyRXNGTDNmWkUzbi1DUVBNNUFtVHFhVlE4OUtQS1pTMHNyWnJpb21qenB2V21OY0sxVkthUHJQQjhJZGtXS3NOWVBhWS1QOFl5bXowQQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Moleculin Biotech secures Hong Kong patent for Annamycin", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZEtwSGZucFBSZHJoaGpCdHFXWXFnNnRMT3VyNHRqLUFON0s3NjlOLTJrSm5ibG1ET3FUeWZVOTd0bkZud1hhNEhTVXBHenBmOW82WHAtbmVVcFpYY1R2UTRZVHNhbVU0UzJueUh2cGRYS3I2bjZFdWpVNVpfbkd3bUZUMXAxMFhGV3BoTUF0enptN1dYMzVpMG5keU1XZXJRREN1OHpFZUtOUVZObk9heVU0dw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech stock plunges after warrant exercise agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNQ3FTSDdpYVY1WDFQcFc0STJoUUUySWhBV0kwTmV0U1p3R0dvTWlsQ0pCWUdvUzF0T2F1RXA4REN1LUFsdEptLTJ3TU54Qmg3NTk1RXZOZmpzS09LMzV1UnAwLXVhZi1DQVZMX2NHdXpIZEZFdzdCOGx2c2loUzZqV29ZVC1SdkZjRE1tcTVOOU5lSUR4UGdYTmdteDZlSnZGaVFvLVBUaTVaVm1ZV1lKLWxGVWQ5WV9mZmh4anYwSWhRS0Fy?oc=5", "source_name": "Investing.com", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Announces Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPemJoaV9WbGNVWDI3aHNja3o0SDA3RThORmtTUk5iVnBUT1h4MUhObF9USzFiSDgxa1ZqanR6TmJGa2lCd2p4ZHRWa0NkRUtmUTJJN0dFWTlPVHNyZnh5azlqaWVZT2c0UW1VR25KQ3poLWxMeVIwRDhVVGRVa2huSXJYMEg?oc=5", "source_name": "citybiz", "published_at": "2025-11-30T08:00:00+00:00", "published_display": "30 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPTkZzdG54MGFVb3hNZ1pCS1FSdEItTjZYNmMwQWdaZVZpY3RrZWRqUlhsTHFvRW9teHlCRUlKRUNDdm5IaGN0ZFlFNDAtSGZwR3NIeDFSN0stTmY3MUNmRVhieW9HT0VJNldzbHAwZDcyLU82WUdMaW0weXBCZDdUcm4yNHZDMVpDQ2w2cEVhLUV6ZkV2UjBwM29jZ25nVkRPNUI0NFZvOEQ5azBEVWtFTk9VMVFIRU9rS3pYUmVRc1JFM2hh?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech stock drops after announcing 1-for-25 reverse split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVTFrZ0lzam9xSVJIOFJqZUUzQW1Rd25mTU5HRU11NUM1YU90WGZvN1Y5MEFNdUFlbkdEVllBdG5aTW8yYzlzMDBrTjEwNHZTeEFLblVCdHhSOE12aW8zeFNaSzBEX3hoWGFZVU05eDlTOGRLUlhja0NRV0Y0bGF0Y1ZPcjg5aDFEX24xcmhCUDdZMzR3TGs4bTN2dW1NdWx0ZldGZDlPd3ZtSDVxTDB6NzFqNzZLY0tFSHFKWU5XT3BwMkhBYzdtdQ?oc=5", "source_name": "Investing.com", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech (MBRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE9ISG44UmN5OWhmX1hDMnRJQ3V5YjBGcVVxR29odk42MDVYaFh6WU4tRXhCaUpWNG5tV2VFZTFTaExYSVplaVktWlNCeS1UZVo2N2RrWkZuYW85M1NoLVNzQnFqZk56M3FV?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T15:48:29+00:00", "published_display": "09 Jul 2025 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOWXk4aklwck0tTWtFYkluLThYNGtxX3RHTHE0YlM2WnFRZG1YTk5mSW5oLVgzVGI3VW4zcTJVeWRDX2JyYWxLaVZ3cEVZS1k3OW56dkZqTnAtS2d4bzY1c2hOdTQ4c0FmeDF5Njdlam1KZURTSGNJMzZPQU9FY18tX3QxUzdCbmVfbEpMbWdJamZIVUVTVkVOUWhvTTN2LUs3Zmx0VG41dWo3Zw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-23T11:18:04+00:00", "published_display": "23 Jul 2026 11:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Moleculin Biotech, Inc. \u2013 GETTEX:MOL0", "summary": "This article provides the \"Price to sales forward\" metric for Moleculin Biotech, Inc. (MOL0) on the GETTEX exchange. The content is primarily a data point embedded within a larger financial platform, indicating a value of \"No trades\" for the specified period.", "url": "https://www.tradingview.com/symbols/GETTEX-MOL0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T07:12:16", "published_display": "13 Jul 2026 07:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Moleculin Biotech, Inc. \u2013 GETTEX:MOL0", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Moleculin Biotech, Inc. (GETTEX:MOL0). The main content consists of the company name, stock ticker, and the specific financial metric. The article is from TradingView and indicates a market-closed status f", "url": "https://www.tradingview.com/symbols/GETTEX-MOL0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T22:09:31", "published_display": "12 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Moleculin Biotech, Inc. \u2013 GETTEX:MOL0", "summary": "This article displays the \"Price to book forward\" for Moleculin Biotech, Inc. (GETTEX:MOL0). It presents a data point under the \"Financials\" section for a specific period, detailing its value and change percentages. The content is presented within the TradingView platform, focusi", "url": "https://www.tradingview.com/symbols/GETTEX-MOL0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T19:39:55", "published_display": "11 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did MBRX Stock Climb 14% Today?", "summary": "Moleculin Biotech's stock (MBRX) surged 14% after the company announced it is on track to treat the 45th patient in its Miracle study for Annamycin by Q1 2026. The drug is being investigated for acute myeloid leukemia, with preliminary data showing a 40% complete remission rate i", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-mbrx-stock-climb-today/cZR0CkIR4vA", "source_name": "Stocktwits", "published_at": "2026-07-11T18:40:04", "published_display": "11 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Moleculin Biotech, Inc. \u2013 NASDAQ:MBRX", "summary": "This article provides financial data for Moleculin Biotech, Inc. (NASDAQ: MBRX), specifically focusing on its enterprise value to EBITDA forward. The content is presented within the TradingView platform, detailing financial metrics, market information, and company background for ", "url": "https://www.tradingview.com/symbols/NASDAQ-MBRX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T06:45:58", "published_display": "09 Jul 2026 06:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Moleculin Biotech, Inc. \u2013 LSE:0K2H", "summary": "This article displays the \"Price to earnings forward\" metric for Moleculin Biotech, Inc. (LSE:0K2H) on the TradingView platform. The content primarily shows navigation elements and structural information from the platform, indicating where this financial data would be presented. ", "url": "https://www.tradingview.com/symbols/LSE-0K2H/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T00:41:07", "published_display": "08 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech focuses on oncology pipeline and Nasdaq listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQSFh6VWU2Yk5lTVpzem15bWI5clBBRkVoTkNYbFZLekkzdFFZeXBEVUV2XzlXbHFZNTNraGV5NGtnRDlDZTllOEZDVmxFZFp1cWpfOWRiS3ctLUZyOWJGd2hBNjBwYkRIMUVPWmpBQ3Zfa0JBaExUMEhaZkNWV01rZTNXelBqOUJULTcyZHY5emhxa0cteTNNc05Pb3NyeFczNkMxc0RveEI3WV9CY1FUc1FpMUhTOUE3X3BrTENGM29Cdw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin CEO, Walter Klemp, Highlights Positive", "summary": "Moleculin's CEO, Walter Klemp, discussed positive preliminary results from the MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML) during a Virtual Investor \"What This Means\" segment. He highlighted early efficacy trends, summarized key data, an", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322423/0/en/moleculin-ceo-walter-klemp-highlights-positive-preliminary-miracle-trial-results-in-virtual-investor-what-this-means-segment.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T05:45:58", "published_display": "07 Jul 2026 05:45", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor \"What This Means\" Segment", "summary": "Moleculin Biotech, Inc. CEO, Walter Klemp, discussed positive preliminary efficacy results from the MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML) during a Virtual Investor \"What This Means\" segment. He highlighted the significance of early", "url": "https://www.sahmcapital.com/news/content/moleculin-ceo-walter-klemp-highlights-positive-preliminary-miracle-trial-results-in-virtual-investor-what-this-means-segment-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-06T15:33:00", "published_display": "06 Jul 2026 15:33", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor 'What This Means' Segment", "summary": "Moleculin Biotech, Inc. CEO, Walter Klemp, discussed positive preliminary unblinded efficacy results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML). He provided insights into ear", "url": "https://www.manilatimes.net/2026/07/06/tmt-newswire/globenewswire/moleculin-ceo-walter-klemp-highlights-positive-preliminary-miracle-trial-results-in-virtual-investor-what-this-means-segment/2379051/amp", "source_name": "The Manila Times", "published_at": "2026-07-06T13:09:54", "published_display": "06 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segment", "summary": "Moleculin Biotech's CEO, Walter Klemp, discussed positive preliminary unblinded efficacy results from the first 45 patients in the pivotal Phase 2/3 MIRACLE trial for Annamycin, a treatment for relapsed or refractory acute myeloid leukemia (R/R AML). While the preliminary data sh", "url": "https://www.quiverquant.com/news/Moleculin+Biotech+CEO+Discusses+Preliminary+MIRACLE+Trial+Results+for+Annamycin+in+Virtual+Investor+Segment", "source_name": "Quiver Quantitative", "published_at": "2026-07-06T12:44:00", "published_display": "06 Jul 2026 12:44", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin says early MIRACLE trial data support Annamycin in leukemia", "summary": "Moleculin CEO Walter Klemp discussed positive preliminary efficacy results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML). The discussion highlighted early efficacy trends across", "url": "https://www.stocktitan.net/news/MBRX/moleculin-ceo-walter-klemp-highlights-positive-preliminary-miracle-jfdzs9iv2o74.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:41:42", "published_display": "06 Jul 2026 12:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech | 8-K: Current report", "summary": "This document is an 8-K filing by Moleculin Biotech, indicating a current report with the SEC. It likely contains information on significant events or changes within the company that shareholders should be aware of.", "url": "https://www.moomoo.com/news/notice/307476918/moleculin-biotech-8-k-current-report", "source_name": "Moomoo", "published_at": "2026-07-06T05:09:54", "published_display": "06 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MBRX - Moleculin Biotech Inc Dividends", "summary": "This article provides comprehensive financial data for Moleculin Biotech Inc (MBRX), including its last close price, market capitalization, income, sales, key financial ratios, and performance metrics. It details the company's dividend estimates, earnings per share, insider and i", "url": "https://finviz.com/stock?t=MBRX&ty=dv&p=w", "source_name": "Finviz", "published_at": "2026-07-04T13:10:14", "published_display": "04 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annamycin boosts remission in Moleculin (MBRX) pivotal AML MIRACLE trial interim", "summary": "Moleculin Biotech (MBRX) reported positive interim results from its pivotal Phase 2/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (AML), showing Annamycin achieved significantly higher remission rates compared to the control arm after a single treatment cycle.", "url": "https://www.stocktitan.net/sec-filings/MBRX/8-k-moleculin-biotech-inc-reports-material-event-2d3624e9981d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:45", "published_display": "02 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10", "summary": "Maxim Group has reiterated its Buy rating for Moleculin Biotech (MBRX.US) and maintained its target price at $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72348333/maxim-group-maintains-moleculin-biotech-mbrxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-02T02:22:18", "published_display": "02 Jul 2026 02:22", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin reports positive interim data from AML trial", "summary": "Moleculin Biotech, Inc. announced positive interim data from the first 45 patients in Part A of its Phase 2/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia, causing its stock to surge. The trial's experimental Annamycin arms showed higher complete remission rate", "url": "https://www.investing.com/news/company-news/moleculin-reports-positive-interim-data-from-aml-trial-93CH-4767922", "source_name": "Investing.com", "published_at": "2026-07-01T03:39:11", "published_display": "01 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. Financial Disclosures & Filings", "summary": "This page provides an extensive list of Moleculin Biotech, Inc.'s financial disclosures and regulatory filings, including earnings reports, corporate presentations, and study updates from 2022 to 2026. The documents offer insights into the company's performance, strategy, and adv", "url": "https://www.tradingview.com/symbols/LSE-0K2H/documents/", "source_name": "TradingView", "published_at": "2026-07-01T02:32:40", "published_display": "01 Jul 2026 02:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance", "summary": "Shares of Moleculin Biotech (MBRX) plunged over 25% after interim data from its Annamycin clinical trial for acute myeloid leukemia did not achieve statistical significance, despite showing a trend favoring the drug. The company emphasized that more data from additional patients ", "url": "https://stocktwits.com/news-articles/markets/equity/mbrx-stock-drops-as-moleculin-biotech-interim-cancer-trial-data-falls-short-of-significance/cZ1QYEmR70m", "source_name": "Stocktwits", "published_at": "2026-06-30T18:52:00", "published_display": "30 Jun 2026 18:52", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 \"Miracle\" clinical trial, showing positive data.", "summary": "Moleculin Biotech, Inc. (Moleculin) has announced positive interim analysis results from its phase 2/3 \"Miracle\" clinical trial. The core candidate drug, Annamycin, demonstrated significantly superior efficacy in inducing complete remission for acute myeloid leukemia, achieving a", "url": "https://www.bitget.com/amp/news/detail/12560605483769", "source_name": "Bitget", "published_at": "2026-06-30T14:40:56", "published_display": "30 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. Shares June 2026 Investor Presentation and Key Regulatory Updates", "summary": "Moleculin Biotech, Inc. has released an investor presentation and provided key regulatory updates. The company received approximately $2.7 million from warrant exercises, increasing its outstanding shares to 7,065,000. These updates are intended to inform investors about the comp", "url": "https://www.minichart.com.sg/2026/06/30/moleculin-biotech-inc-shares-june-2026-investor-presentation-and-key-regulatory-updates/", "source_name": "Minichart", "published_at": "2026-06-30T13:02:00", "published_display": "30 Jun 2026 13:02", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Reports Positive Phase 2/3 MIRACLE Interim", "summary": "Moleculin Biotech, Inc. announced positive preliminary unblinded efficacy results from the", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319693/0/en/moleculin-reports-positive-phase-2-3-miracle-interim-results-with-annamycin-complete-remission-rates-3-fold-greater-than-control.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:39:40", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8-K Moleculin Biotech, Inc. For: Jun 30", "summary": "Moleculin Biotech, Inc. filed a Form 8-K announcing positive preliminary unblinded efficacy results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin. The study, analyzing 45 patients with relapsed or refractory acute myeloid leukemia (R/R AML), showed favorable ef", "url": "https://www.streetinsider.com/SEC+Filings/Form+8-K+Moleculin+Biotech%2C+Inc.+For%3A+Jun+30/26710215.html", "source_name": "StreetInsider", "published_at": "2026-06-30T12:39:40", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech (NASDAQ: MBRX) raises $2.7M as 1.36M warrants are exercised", "summary": "Moleculin Biotech (NASDAQ: MBRX) has reported raising approximately $2.7 million from the exercise of warrants covering 1.36 million shares of common stock. Following these exercises, the company now has 7,065,000 shares of common stock outstanding as of June 29, 2026. Moleculin ", "url": "https://www.stocktitan.net/sec-filings/MBRX/8-k-moleculin-biotech-inc-reports-material-event-639e24daf682.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:11:03", "published_display": "30 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX)", "summary": "This article provides an overview of Moleculin Biotech, Inc. (NASDAQ: MBRX) stock, including its current price, historical performance, analyst forecasts, and financial data. It details recent earnings, revenue, net income, and market capitalization, while also answering frequent", "url": "https://www.tradingview.com/symbols/NASDAQ-MBRX/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-29T09:11:56", "published_display": "29 Jun 2026 09:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control", "summary": "Moleculin Biotech, Inc. announced positive preliminary unblinded efficacy results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (R/R AML). Both Annamycin treatment arms demonstrated significantly high", "url": "https://finance.yahoo.com/healthcare/articles/moleculin-reports-positive-phase-2-123000165.html", "source_name": "Market source", "published_at": "2026-06-28T09:09:38", "published_display": "28 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MBRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a stock forecast for Moleculin Biotech, Inc. (MBRX), including analyst price targets, historical performance, and key financial data. It notes that analysts predict a maximum price of $22.00 and a minimum of $10.00 for MBRX. The company's current stock price", "url": "https://www.tradingview.com/symbols/NASDAQ-MBRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T03:40:37", "published_display": "27 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "0K2H Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Moleculin Biotech, Inc. (0K2H) stock, listed on the London Stock Exchange. It includes analyst ratings, future price estimates, and key financial metrics such as earnings, revenue, and market capitalization. The stock's perfor", "url": "https://www.tradingview.com/symbols/LSE-0K2H/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T00:39:26", "published_display": "26 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. Actuals & Estimates (LSE:0K2H)", "summary": "This article provides an overview of Moleculin Biotech, Inc. (LSE:0K2H) stock performance, financial actuals, and analyst estimates. It details recent price changes, historical highs and lows, market capitalization, and upcoming earnings reports. The piece also includes frequentl", "url": "https://www.tradingview.com/symbols/LSE-0K2H/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:47", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech (MBRX) CFO exercises RSUs, uses shares to cover taxes", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQLW9lN05HZ09mWUNid3dtVW14Zl90LWp3WDk4cFkzR29YMlRBb096TXA2dzZqTkZrelhUeUUzc0I0NTE4SUtnakctSkVidkJtVkhyS201N1lIZ2ppZndOLWhiaGJlYWxpc3Z0ZzVibndqelI4ZHVvN1NHOUlmQjNtNEt2aEUtLTc2Mko3ODZjLU5lNUtHWjZHX0dUdUZUSG1xZ2hqbUlpSko5UXMyeElwMHNCa2ZrUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech (MBRX) CEO reports RSU vesting, tax-share withholding and retained stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPcWhFalNhNDVLeUtJYmQ4QXgzX1VIVTNlbmtYbVJCWnQ4SGFNcTVIQnNnWm40MWhfNU5uYUNRSG9wdUtxcXk1dDJmVVVNUTVDU2ZRSVhtY20tS29YUTRWUHNueFByNmMyOG1DUC0xbVp4VDVZSTdKOWljVnVHVE1lSFNZMEJ2cC1xcUwzbzdpOWx5S1U1S003ZGNMeGRQUnVKUVpKQlEtbTQtbTA0Z1FraGcyRFc2UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | Moleculin Biotech Shoots up 106.41% Pre-Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOWjRJWHNERUx2RkYzOWZQZ0RxZ25ZbU5pOTA0N1ZnTXFfellQcERQLWFoNmR0dDY1cUhVRTNCU21KRUNKZXpnblhCUzdsWHltdzFlRlhiYjhyNWQ5R3R5aWNjWnJnS2JXNHNWS1NXNlFXVm1WMUpHYTNwV3J6Ymc1SW53MlRsLU1HWWRMMENxT2hEN1dSUFZCZndUY3dBajVrUHpNdQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Moleculin Biotech (MBRX.US)$", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNVGFtVDRad014Y2NJUzR6M2cyRHduOWVJWW9KX0pUVzJ5cUl4ZFBZTTBRaFNjclRIcFdlaW5fWWFnNFJyX0dUUjFtODVSZVJ6X19tVnRkVF92RjQzS2I1MDN2OVp6NE1uTDAtaFBwZVhCV0ZNRFFRTGo5LVBFX1lSNWJ0aHdOQQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/independent-market-research-finds-strong-122900069.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T12:29:00+00:00", "published_display": "05 Jun 2026 12:29", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/moleculin-ceo-walter-klemp-highlights-123100538.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:31:00+00:00", "published_display": "04 Jun 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/moleculin-presents-asco-2026-data-122100249.html", "source_name": "GlobeNewswire", "published_at": "2026-05-29T12:21:00+00:00", "published_display": "29 May 2026 12:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/moleculin-highlights-abstract-accepted-poster-210200148.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:02:00+00:00", "published_display": "21 May 2026 21:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/moleculin-reports-first-quarter-2026-123000136.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T12:30:00+00:00", "published_display": "15 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding", "summary": "", "url": "https://finance.yahoo.com/news/nano-cap-moleculin-biotech-approaches-164146755.html", "source_name": "Benzinga", "published_at": "2026-05-13T16:41:46+00:00", "published_display": "13 May 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks", "summary": "", "url": "https://finance.yahoo.com/news/moleculin-announces-imminent-miracle-trial-120000284.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T12:00:00+00:00", "published_display": "13 May 2026 12:00", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech (MBRX) Approaches Key Data Release in AML Tria", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQX2pFbHNKMzRQbkhBNm1LMmJBbC0xaEhQeEl4Tkh6UlhBb3RvNk5KRHgyWFRjcEtBOWl1ZHNndlVPNTc2OG9EbEFhRzVfSk9fY1BENmRhbFV6amUzSDNXdzVwelJISWNnaU5hamctUlM2TzNBa2h4Nk5XajVXVWdlVUFXWk5DWEYtYUNheVYyRXNGTDNmWkUzbi1DUVBNNUFtVHFhVlE4OUtQS1pTMHNyWnJpb21qenB2V21OY0sxVkthUHJQQjhJZGtXS3NOWVBhWS1QOFl5bXowQQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech secures Hong Kong patent for Annamycin", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZEtwSGZucFBSZHJoaGpCdHFXWXFnNnRMT3VyNHRqLUFON0s3NjlOLTJrSm5ibG1ET3FUeWZVOTd0bkZud1hhNEhTVXBHenBmOW82WHAtbmVVcFpYY1R2UTRZVHNhbVU0UzJueUh2cGRYS3I2bjZFdWpVNVpfbkd3bUZUMXAxMFhGV3BoTUF0enptN1dYMzVpMG5keU1XZXJRREN1OHpFZUtOUVZObk9heVU0dw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech stock plunges after warrant exercise agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNQ3FTSDdpYVY1WDFQcFc0STJoUUUySWhBV0kwTmV0U1p3R0dvTWlsQ0pCWUdvUzF0T2F1RXA4REN1LUFsdEptLTJ3TU54Qmg3NTk1RXZOZmpzS09LMzV1UnAwLXVhZi1DQVZMX2NHdXpIZEZFdzdCOGx2c2loUzZqV29ZVC1SdkZjRE1tcTVOOU5lSUR4UGdYTmdteDZlSnZGaVFvLVBUaTVaVm1ZV1lKLWxGVWQ5WV9mZmh4anYwSWhRS0Fy?oc=5", "source_name": "Investing.com", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Announces Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPemJoaV9WbGNVWDI3aHNja3o0SDA3RThORmtTUk5iVnBUT1h4MUhObF9USzFiSDgxa1ZqanR6TmJGa2lCd2p4ZHRWa0NkRUtmUTJJN0dFWTlPVHNyZnh5azlqaWVZT2c0UW1VR25KQ3poLWxMeVIwRDhVVGRVa2huSXJYMEg?oc=5", "source_name": "citybiz", "published_at": "2025-11-30T08:00:00+00:00", "published_display": "30 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPTkZzdG54MGFVb3hNZ1pCS1FSdEItTjZYNmMwQWdaZVZpY3RrZWRqUlhsTHFvRW9teHlCRUlKRUNDdm5IaGN0ZFlFNDAtSGZwR3NIeDFSN0stTmY3MUNmRVhieW9HT0VJNldzbHAwZDcyLU82WUdMaW0weXBCZDdUcm4yNHZDMVpDQ2w2cEVhLUV6ZkV2UjBwM29jZ25nVkRPNUI0NFZvOEQ5azBEVWtFTk9VMVFIRU9rS3pYUmVRc1JFM2hh?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech stock drops after announcing 1-for-25 reverse split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVTFrZ0lzam9xSVJIOFJqZUUzQW1Rd25mTU5HRU11NUM1YU90WGZvN1Y5MEFNdUFlbkdEVllBdG5aTW8yYzlzMDBrTjEwNHZTeEFLblVCdHhSOE12aW8zeFNaSzBEX3hoWGFZVU05eDlTOGRLUlhja0NRV0Y0bGF0Y1ZPcjg5aDFEX24xcmhCUDdZMzR3TGs4bTN2dW1NdWx0ZldGZDlPd3ZtSDVxTDB6NzFqNzZLY0tFSHFKWU5XT3BwMkhBYzdtdQ?oc=5", "source_name": "Investing.com", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moleculin Biotech (MBRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE9ISG44UmN5OWhmX1hDMnRJQ3V5YjBGcVVxR29odk42MDVYaFh6WU4tRXhCaUpWNG5tV2VFZTFTaExYSVplaVktWlNCeS1UZVo2N2RrWkZuYW85M1NoLVNzQnFqZk56M3FV?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T15:48:29+00:00", "published_display": "09 Jul 2025 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 58, "sentiment_summary": {"positive": 16, "negative": 5, "neutral": 37, "score": 55, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 76, "events": [{"event": "earnings", "label": "Earnings", "weight": 14.51, "count": 28}, {"event": "general", "label": "Market update", "weight": 14.1, "count": 25}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 2.1, "latest_week": "2026-07-17", "one_week_move": -7.9, "four_week_move": -27.1, "twelve_week_move": -17.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.11473, "market_dynamics_buy_signal": false, "relative_strength": -71.609969, "fair_value_gap": -97.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.725, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.9% over one week, -27.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "GlobeNewswire", "count": 8}, {"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "Stocktwits", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 28}, {"label": "Market update", "count": 25}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-7.9% over one week, -27.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)"}], "updated_at": "2026-07-23T20:03:40.166412+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}